10-K: Plus Therapeutics Reports 2024 Results, Highlights Clinical Progress and Strategic Initiatives

Plus Therapeutics' 2024 10-K filing details ongoing clinical trials for REYOBIQ, acquisition of the CNSide Platform, and efforts to secure additional funding amidst financial uncertainties.

Summary

• Plus Therapeutics, Inc., a pharmaceutical company focused on targeted radiotherapeutics for central nervous system cancers, filed its Form 10-K for the year ended December 31, 2024.
• The company is developing REYOBIQ, a radiotherapeutic candidate for CNS cancers, and Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188 RNL-BAM) for solid organ cancers.
• In April 2024, Plus Therapeutics acquired the CNSide Platform, a cerebrospinal fluid cancer diagnostic portfolio, and plans to re-introduce the CNSide Test to the U.S. market in the second quarter of 2025.
• The company's lead drug, REYOBIQ, has shown potential in treating recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC).
• Clinical trials for REYOBIQ are ongoing, including the ReSPECT-GBM trial for recurrent GBM and the ReSPECT-LM trial for LM, with funding from the National Institutes of Health and the Cancer Prevention and Research Institute of Texas (CPRIT).
• The company completed Phase 1 of the ReSPECT-LM trial and determined a recommended Phase 2 dose, with plans to begin a multi-dose trial in the first half of 2025.
• Plus Therapeutics is also developing 188 RNL-BAM for liver cancer, which the FDA will regulate as a medical device.
• The company faces competition from other entities pursuing drug development programs for similar indications.
• Plus Therapeutics relies on a combination of patents, trade secrets, and licensing agreements to protect its intellectual property.
• The company is subject to extensive government regulations and requires regulatory approvals to market its product candidates.
• Plus Therapeutics incurred a net loss of $13.0 million in 2024 and has an accumulated deficit of $493.5 million.
• The company needs substantial additional funding to continue its operations and develop its product candidates.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's common stock is listed on the Nasdaq Capital Market, and it must comply with Nasdaq's continued listing requirements.
• The company is subject to various federal and state healthcare laws and regulations, including anti-kickback statutes and false claims laws.
• The company expects to incur significant net losses in the foreseeable future and may never become profitable.
• The company's future success depends on its ability to successfully develop and commercialize its nanomedicine platform and product candidates.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's progress in clinical trials and strategic acquisitions, the company's financial position raises concerns about its long-term viability. The need for additional funding and the competitive landscape add to the uncertainty.

Positives

• REYOBIQ has received orphan drug and Fast Track designations from the FDA.
• The company has secured grant funding from NIH, CPRIT, and the Department of Defense.
• The CNSide TM Test influenced treatment decisions in over 90% of cases evaluated, surpassing the predetermined 20% primary endpoint target.
• The CNSide TM Test demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM.
• The CNSide TM Test identified actionable mutations in the CSF, such as HER2 amplification, influencing 24% of therapeutic selection decisions.
• The CNSide TM Test exhibited high specificity, with no tumor cells detected in patients without LM.
• The CNSide TM Test demonstrated improved Negative Predictive Value in ruling out LM (25%) vs. CSF cytology (10%).
• The CNSide TM Test revealed HER2 positivity in LM tumors in 60% of breast cancer patients with HER2-negative primary tumors, informing physician treatment strategies.

Negatives

• The company has incurred net losses since inception and expects to incur significant net losses in the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company could be delisted from Nasdaq for failure to comply with the minimum stockholders equity continued listing requirement.
• The company will need substantial additional funding to develop its product candidates and conduct its future operations.
• The company maintains its cash at financial institutions, often in balances that exceed federally insured limits.
• The company may decide to pursue a particular product candidate and fail to advance product candidates that later demonstrate a greater chance of clinical and commercial success.
• The company may have difficulty enrolling, or fail to enroll patients in its clinical trials, which could delay or prevent clinical trials of its drug candidates.
• The company may be unable to receive regulatory approval or market acceptance for such product candidate if a particular product candidate causes significant adverse events.
• The company may not generate sufficient revenue from these products to become or remain profitable if its product candidates and technologies do not achieve an adequate level of acceptance by physicians, pharmacists and patients.

Risks

• The company has incurred losses since inception and expects to incur significant net losses in the foreseeable future.
• Uncertainties relating to the company's ability to fund its operations for at least the next 12 months raises substantial doubt about its ability to continue as a going concern.
• The company could be delisted from Nasdaq for failure to comply with the minimum stockholders equity continued listing requirement.
• The company will need substantial additional funding to develop its product candidates and conduct its future operations.
• The company's future success is dependent upon its ability to successfully develop its nanomedicine platform and commercialize REYOBIQ and 188 RNL-BAM.
• The company may not be successful in its efforts to develop, fully utilize and monetize the CNSide TM Portfolio.
• The company's success depends in substantial part on its ability to obtain regulatory approvals for its RNL product candidates.
• The company's current business strategy is high-risk and may not be successful.
• Reliance on government funding for the company's programs may impose requirements that limit its ability to take certain actions.
• If the company's competitors market or develop products that are marketed more effectively, approved more quickly than its product candidates, its commercial opportunities could be reduced or eliminated.
• The company may have difficulty enrolling, or fail to enroll patients in its clinical trials, which could delay or prevent clinical trials of its drug candidates.
• If a particular product candidate causes significant adverse events, then the company may be unable to receive regulatory approval or market acceptance for such product candidate.
• If the company's product candidates and technologies receive regulatory approval but do not achieve broad market acceptance, the revenue that it generates will be limited.
• The company and its product candidates are subject to extensive regulation, and the requirements to obtain regulatory approvals in the United States and other jurisdictions can be costly, time-consuming and unpredictable.
• Adequate coverage and reimbursement from third party payors may not be available for the company's product candidates, which could diminish its sales or adversely affect its ability to sell its products profitably.
• The company may engage in strategic transactions that could impact its liquidity, increase its expenses, and present significant distractions to its management.
• The company faces potential product liability exposure, and if successful claims are brought against it, it may incur substantial liability if its insurance coverage for those claims is inadequate.
• The company's stockholders may experience substantial dilution in the value of their investment if it issues additional shares of its capital stock.
• The market price of the company's common stock may be volatile and fluctuate significantly, which could result in substantial losses for stockholders.

Future Outlook

The company expects grant revenue will increase during the remaining term of the CPRIT Grant through August 2025, as it continues to expand the LM clinical trial. Aggregate research and development expenditures are expected to increase significantly during 2025 compared to 2024, due to increased costs for the ReSPECT-LM clinical trial and increases in licensing payments.

Industry Context

The company operates in the intensely competitive and highly regulated life science industry, facing competition from numerous companies, academic institutions, and research institutions. The company's product candidates, if approved, would compete on the basis of product efficacy and safety, time to market, price, coverage, and reimbursement by third-party payers, extent of adverse side effects, and convenience of treatment procedures.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• The document mentions several competitors in the recurrent glioblastoma, leptomeningeal metastases, pediatric brain cancer, and liver cancer spaces, but does not provide enough information to compare Plus Therapeutics' results to those of its competitors.
• For example, the document mentions Boston Scientific, SIR-TEX, and Terumo as competitors in the liver cancer radioembolization therapy space, but does not provide enough information to compare Plus Therapeutics' 188 RNL-BAM technology to those of its competitors.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional shares of capital stock.
• Employees' job security is uncertain due to the company's financial situation.
• Customers (patients) may benefit from the development of new cancer treatments.
• Suppliers and creditors face the risk of non-payment if the company's financial situation worsens.

Next Steps

• Targeting full enrollment into Phase 2 of ReSPECT-GBM Trial by the end of 2025.
• Beginning enrollment for a ReSPECT-LM Multi-Dose trial in the first half of 2025.
• Beginning enrollment for Phase 1 ReSPECT-PBC clinical trial in the first half of 2025.
• Seeking stockholder approval to amend the Certificate of Incorporation to increase the authorized share capital to an amount sufficient to cover the shares of Common Stock issuable upon the exercise of the Series A Warrants and Series B Warrants.

Key Dates

Keywords

REYOBIQ, glioblastoma, leptomeningeal metastases, pediatric brain cancer, radiotherapeutics, clinical trials, CNSide Platform, Rhenium-188, nanoliposomes, cancer, FDA, LM, GBM, PBC